Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
US VC launches another biotech with China-licensed asset
Aditum is offering up to $1 billion biobucks to Mabwell for exclusive global licensing rights to a dual-target siRNA candidate.
Gabrielle Masson
Sep 17, 2025 10:30am
Novartis returns to Argo for $5B cardiovascular collab
Sep 3, 2025 9:15am
Novartis aims at alpha-synuclein again with $2.2B Arrowhead deal
Sep 2, 2025 9:55am
Regeneron posts phase 3 win, advancing push to muscle in on gMG
Aug 26, 2025 9:41am
RNA biotech emerges with $52M and clinical rare disease asset
Aug 25, 2025 10:13am
Federal mRNA vax grant cuts includes unrelated project
Aug 7, 2025 2:20pm
